EP3463304A4 - Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations - Google Patents

Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Download PDF

Info

Publication number
EP3463304A4
EP3463304A4 EP17802329.7A EP17802329A EP3463304A4 EP 3463304 A4 EP3463304 A4 EP 3463304A4 EP 17802329 A EP17802329 A EP 17802329A EP 3463304 A4 EP3463304 A4 EP 3463304A4
Authority
EP
European Patent Office
Prior art keywords
cannabidiol
compositions
treatment
hyaluronic acid
joint diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP17802329.7A
Other languages
German (de)
English (en)
Other versions
EP3463304A1 (fr
Inventor
Tamir GEDO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bol Pharma Ltd
Original Assignee
Bol Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bol Pharma Ltd filed Critical Bol Pharma Ltd
Publication of EP3463304A1 publication Critical patent/EP3463304A1/fr
Publication of EP3463304A4 publication Critical patent/EP3463304A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP17802329.7A 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations Withdrawn EP3463304A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662340576P 2016-05-24 2016-05-24
PCT/IL2017/050580 WO2017203529A1 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Publications (2)

Publication Number Publication Date
EP3463304A1 EP3463304A1 (fr) 2019-04-10
EP3463304A4 true EP3463304A4 (fr) 2020-01-08

Family

ID=60411168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17802329.7A Withdrawn EP3463304A4 (fr) 2016-05-24 2017-05-24 Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations

Country Status (4)

Country Link
EP (1) EP3463304A4 (fr)
CA (1) CA3025208A1 (fr)
IL (1) IL263174A (fr)
WO (1) WO2017203529A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
AU2019299213A1 (en) * 2018-07-02 2021-02-11 Companion Sciences, Llc Cannabidiol combination compositions
WO2020021545A1 (fr) * 2018-07-25 2020-01-30 Bol Pharma Ltd. Cannabidiol et glucosamine pour le traitement de maladies articulaires inflammatoires
WO2020024056A1 (fr) * 2018-08-01 2020-02-06 Lazar Eve Compositions comprenant des cannabinoïdes et matériau absorbable et utilisations associées
KR20210116432A (ko) * 2018-10-10 2021-09-27 틸레이, 인크. 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형
CA3119037A1 (fr) * 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions pour l'administration d'agents therapeutiques et leurs methodes d'utilisation et leurs procedes de preparation
US20220054532A1 (en) * 2019-03-05 2022-02-24 Colleen Smith Veterinary compositions and methods of use therefor
KR20210151816A (ko) 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
US20200352849A1 (en) * 2019-05-07 2020-11-12 Adam M. Rotunda Topical Skin Formulations and Wound Care Products with Integrated CBD Delivery Mechanisms for Skin Rejuvenation, Wound Care and Healing, Pain and Itch Relief, and Scar Prevention and Treatment
IT201900008409A1 (it) * 2019-06-07 2020-12-07 Vivatis Pharma Gmbh Individuazione e selezione di un materiale di partenza vegetale di condroitina solfato e acido ialuronico vegetali, e trasformazione di tale materiale di partenza vegetale per l’ottenimento di ingredienti per utilizzo in alimenti, integratori, dispositivi medici o farmaci
JP7770688B2 (ja) * 2019-10-03 2025-11-17 イッサム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッド リポソームカンナビノイドおよびその使用
WO2021091905A1 (fr) * 2019-11-08 2021-05-14 Vella Bioscience, Inc. Formulations liposomales pour l'administration de cannabinoïdes et leurs procédés de fabrication
US20230010871A1 (en) * 2019-12-13 2023-01-12 Folium Labs Inc. Complexes comprising a carbohydrate polymer and an active ingredient and processes for their preparation
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
EP3861996A1 (fr) 2020-02-04 2021-08-11 I+Med S. Coop. Système de libération contrôlée de formulations de phytocannabinoïdes solubles dans un milieu aqueux, procédés et utilisations associés
CN112138138B (zh) * 2020-11-19 2023-05-23 乐康珍泰（天津）生物技术有限公司 一种用于治疗痛风的药物组合物及其制备方法
WO2022232574A1 (fr) 2021-04-29 2022-11-03 Tilray, Inc. Formulations dans lesquelles le cannabidiol est le constituant dominant, leurs procédés de fabrication et leurs utilisations
US20240226060A1 (en) * 2021-05-03 2024-07-11 Panag Pharma Inc. Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof
IT202200002000A1 (it) * 2022-02-04 2023-08-04 Mak Pharma S R L Composizione orale liposomiale di almeno un principio attivo scarsamente assorbibile a livello intestinale

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (fr) * 2004-06-08 2005-12-22 Gw Pharma Limited Compositions pharmaceutiques destinees au traitement de l'arthrite et/ou de ses symptomes
WO2009018389A1 (fr) * 2007-07-30 2009-02-05 Alltranz Inc. Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation
EP2446884A1 (fr) * 2010-10-29 2012-05-02 China Medical University Composition pharmaceutique comprenant de l'acide hyaluronique et un inhibiteur de l'HMG-CoA réductase pour inhiber l'inflammation
WO2014008469A2 (fr) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Méthodes de traitement de l'arthrite

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5128326A (en) * 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US10004684B2 (en) * 2001-02-14 2018-06-26 Gw Pharma Limited Pharmaceutical formulations
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20110142914A1 (en) * 2007-12-06 2011-06-16 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
US20130184354A1 (en) * 2012-01-13 2013-07-18 Donna K. Jackson Silicone and Hylauronic Acid (HLA) Delivery Systems for Products by Sustainable Processes for Medical Uses Including Wound Management
WO2013114377A1 (fr) * 2012-02-02 2013-08-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd Liposomes stables pour l'administration de médicament
CA2929280A1 (fr) * 2013-10-31 2015-05-14 Full Spectrum Laboratories, Ltd. Formulations de terpene et de cannabinoides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120478A1 (fr) * 2004-06-08 2005-12-22 Gw Pharma Limited Compositions pharmaceutiques destinees au traitement de l'arthrite et/ou de ses symptomes
WO2009018389A1 (fr) * 2007-07-30 2009-02-05 Alltranz Inc. Promédicaments de cannabidiol, compositions comprenant les promédicaments de cannabidiol et leurs procédés d'utilisation
EP2446884A1 (fr) * 2010-10-29 2012-05-02 China Medical University Composition pharmaceutique comprenant de l'acide hyaluronique et un inhibiteur de l'HMG-CoA réductase pour inhiber l'inflammation
WO2014008469A2 (fr) * 2012-07-05 2014-01-09 Taiwan Liposome Company, Ltd. Méthodes de traitement de l'arthrite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017203529A1 *

Also Published As

Publication number Publication date
EP3463304A1 (fr) 2019-04-10
WO2017203529A1 (fr) 2017-11-30
CA3025208A1 (fr) 2017-11-30
IL263174A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
EP3463304A4 (fr) Compositions comprenant du cannabidiol et de l'acide hyaluronique pour le traitement de maladies inflammatoires des articulations
EP3866781A4 (fr) Nouvelles compositions pour le traitement de maladies inflammatoires
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA41010A (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3390634A4 (fr) Compositions et méthodes pour le traitement de maladies oculaires
EP3829569A4 (fr) Formulations de spinosyne pour le traitement de maladies oculaires et faciaux provoquées par demodex
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3639833A4 (fr) Agent pour la prévention ou le traitement de maladies liées à la graisse et/ou de l'inflammation
EP3481387A4 (fr) Methodes et compositions pour le traitement de troubles épileptiques
EP2861246A4 (fr) Compositions et procédés pour l'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de divers troubles et maladies
EP2964761A4 (fr) Composition pharmaceutique comprenant l'arginine déiminase de liaison à l'albumine pour le traitement ciblé du cancer
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3758716A4 (fr) Formulations pour le traitement du reflux acide comprenant de l'alginate de sodium
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA55490A (fr) Mutéine de lipocaline pour le traitement de l'asthme
EP3877383A4 (fr) Composés et compositions pour le traitement de maladies respiratoires
EP3634394A4 (fr) Compositions pour le traitement de maladies neurodégénératives
EP3533451A4 (fr) Application de paeéniflorin-6'-o-benzène sulfonate en médecine pour le traitement du syndrome de sjögren
MA44384A (fr) Formulation d'amidon de pois d'acide polyinosinique-polycytidylique (poly(i:c)) pour la prévention et/ou le traitement d'infections des voies respiratoires supérieures

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191211

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/127 20060101AFI20191205BHEP

Ipc: A61K 47/24 20060101ALI20191205BHEP

Ipc: A61P 19/02 20060101ALI20191205BHEP

Ipc: A61K 47/36 20060101ALI20191205BHEP

Ipc: A61K 31/352 20060101ALI20191205BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211201